Hisham Ahamed

Dr. Hisham Ahamed


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HAHisham Ahamed
Hisham Ahamed
ABAniketh Vijay Balegadde
Aniketh Vijay Balegadde
SMShilpa Menon
Shilpa Menon
RMRamesh Menon
Ramesh Menon
ARAishwarya Ramachandran
Aishwarya Ramachandran
SPSameer Phalke
Sameer Phalke
The PRKAG2 syndrome is a rare autosomal dominant phenocopy of sarcomeric hypertrophic cardiomyopathy (HCM), characterized by ventricular pre-excitation, progressive conduction system disease and left ventricular hypertrophy. This study describes the phenotype, genotype and clinical outcomes of a South-Asian PRKAG2 cardiomyopathy cohort over a 7-year period. Clinical, electrocardiographic, echocardiographic, and cardiac MRI data from 22 individuals with PRKAG2 variants (68% men; mean age 39.5 ± 18.1 years), identified at our HCM centre were studied prospectively. At initial evaluation, all of the patients were in NYHA functional class I or II. The maximum left ventricular wall thickness was 22.9 ± 8.7 mm and left ventricular ejection fraction was 53.4 ± 6.6%. Left ventricular hypertrophy was present in 19 individuals (86%) at baseline. 17 patients had an WPW pattern (77%). After a mean follow-up period of 7 years, 2 patients had undergone accessory pathway ablation, 8 patients (36%) underwent permanent pacemaker implantation (atrio-ventricular blocks—5; sinus node disease—2), 3 patients developed atrial fibrillation, 11 patients (50%) developed progressive worsening in NYHA functional class, and 6 patients (27%) experienced sudden cardiac death or equivalent. PRKAG2 cardiomyopathy must be considered in patients with HCM and progressive conduction system disease.

1 July 2025 in EP Europace
Verified
Journal Article
Open access
AMAkash Mavilakandy
Akash Mavilakandy
Ahmed AbdelrazikAhmed Abdelrazik
Ahmed Abdelrazik
KAKhaled Abouelmagd
Khaled Abouelmagd
IKIvelin Koev
Ivelin Koev
RCRavi Chotalia
Ravi Chotalia
MIMokhtar Ibrahim
Mokhtar Ibrahim
Aims: Atrioventricular node ablation (AVNA) with permanent pacemaker implantation is an established rate-control treatment approach for patients with AF with uncontrolled ventricular rates. Conduction system pacing (CSP) utilizing His bundle pacing (HBP) or left bundle branch area pacing (LBBAP) has advanced as a treatment alternative to standard right ventricular pacing in addition to biventricular pacing (BVP). This systematic review and meta-analysis aim to provide a comprehensive summary and evaluation of clinical outcomes in the literature for CSP in comparison to BVP in conjunction with AVNA. Methods and results: This study protocol was registered in the PROSPERO registry (CRD42024510974), and the review was conducted as per the PRISMA guidelines. Databases were searched for relevant studies from inception till 11 January 2024. Results were synthesized using a random effects meta-analysis. From a total of 259 references identified, 122 full texts were assessed, and 25 studies were included in the systematic review. Of these included studies, five were used for comparative meta-analysis. A total of 1652 (HBP 1069 and LBBAP 644) and 369 patients received CSP and BVP implantation with AVNA, respectively. Conduction system pacing resulted in a narrower QRS duration (QRSd) with a change of −35.8 ms (95% CI −61.8 to −9.72; P < 0.05; I2 = 96.3%) vs. BVP. Conduction system pacing also resulted in better symptomatic improvement in from of NYHA reduction (MD −0.53, 95% CI −1.01 to −0.04, I2 = 62.1; P = 0.03). For left ventricular ejection fraction, a non-significant weighted mean increases of 3.36% (95% CI −0.75–7.47%; P = 0.11, I2 = 68.5%) was observed following CSP implantation in comparison to BVP. Conduction system pacing showed no significant differences in procedural and fluoroscopy times and had comparable periprocedural complications. His bundle pacing demonstrated a non-significant reduction in the events of acute threshold elevation in comparison to BVP (Log odds ratio −0.69, 95% CI −2.05–0.66, I2 = 0.00; P = 0.32). Conclusion: Conduction system pacing with AVNA is a safe and feasible treatment option for symptomatic (AF) patients undergoing a pace and ablate strategy, offering an alternative to BVP. Overall, CSP results in a narrower QRS duration while providing comparable clinical and echocardiographic outcomes.

9 December 2024 in BMJ Paediatrics Open
Verified
Journal Article
Open access
PDF file
MKMalavika Krishnakumar
Malavika Krishnakumar
AHAparna Hari
Aparna Hari
GGGeorg Gutjahr
Georg Gutjahr
PBPerraju Bendapudi
Perraju Bendapudi
HAHisham Ahamed
Hisham Ahamed
MRManu Raj
Manu Raj
Background: The aetiology of congenital heart disease (CHD) is multifactorial. Environmental risk factors have emerged as an important modifiable determinant of several congenital cardiac conditions. Previous studies have shown a strong relationship between CHD and air pollution. Much less is known about the influence of ambient temperature on CHD. The primary objective of this meta-analysis was to examine the association between exposure to extreme heat events (EHE) during pregnancy and CHD in the offspring.Methods: comprehensive literature search was conducted using electronic databases such as Scopus and PubMed, along with a review of secondary references. This process yielded eight studies that met the inclusion criteria: four from the USA, two from China, one from Israel and one from Canada. The risk of bias was assessed using the Newcastle Ottawa scale. Mixed-effect regression was used to pool the estimates of individual studies. Heterogeneity was measured by I2. Results were visualised by a forest plot, a Baujat plot and an albatross plot. Subgroup analyses were performed for climate zones, exposure definitions and the study region. As a sensitivity analysis, a leave-one-out meta-analysis was performed to assess the robustness of the estimates.Results: Exposure to EHE during pregnancy increased the risk for CHD in the offspring (OR=1.12, 95% CI 1.04 to 1.34). Studies from the USA observed the smallest effect (OR=1.01, 95% CI 0.91 to 1.13), studies in the continental climate zone observed a slightly larger effect (OR=1.07, 95% CI 0.97 to 1.19), and studies from the temperate climate zone observed the largest effect (OR=1.35, 95% CI 1.23 to 1.48). Subgroup analysis was conducted with respect to exposure, effect definition and region. The residual heterogeneity measures were 88% (exposure), 61% (effect definition) and 38% (Region).Conclusion: The association between prenatal EHE exposure and future risk of CHD has important implications for pregnant mothers, infant health and health policy. Future studies should explore the additional burden of CHD contributed by current trends in global ambient temperature in other parts of the world.PROSPERO registration number: CRD42023455934

23 January 2024 in JACC: Case Reports
Verified
Journal Article
Open access
HAHisham Ahamed
Hisham Ahamed
AGArun Gopi
Arun Gopi
Multifocal ectopic Purkinje-related premature contraction (MEPPC) is an autosomal dominant SCN5A channelopathy characterized by frequent multiform premature ventricular contractions originating from the His-Purkinje system. We present a patient with an MEPPC phenotype whose genetic testing identified a pathogenic SCN5A (HGNC:10593) variant amenable to precision antiarrhythmic therapy with flecainide.

4 November 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
VRVinay J. Rao
Vinay J. Rao
TSThiagarajan Sairam
Thiagarajan Sairam
ARAndiappan Rathinavel
Andiappan Rathinavel
KMKurukkanparampil Sreedharan Mohanan
Kurukkanparampil Sreedharan Mohanan
HAHisham Ahamed
Hisham Ahamed
PDPerundurai S Dhandapany
Perundurai S Dhandapany
Background: Primary hypertrophic cardiomyopathy ( HCM ) is predominantly a genetic disease causing left ventricular hypertrophy in the absence of other cardiac and systemic metabolic diseases. Currently, limited data exist on the prevalence of clinically actionable gene variants for primary HCM in South Asian Indian ( SAI ) patients, which are necessary for minimizing disparities in interpreting ancestry‐specific variants. The ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel categorized HCM ‐causing genes into 5 categories according to their clinical relevance: definitive, strong, moderate, limited, and disputed. However, comprehensive studies examining this classification in SAI patients are lacking. Methods: Whole‐exome sequencing was performed for 335 primary SAI patients with HCM, including all known cardiovascular genes and clinically actionable gene categories to determine their allele frequencies. Results: SAI HCM exomes revealed a total of 193 pathogenic/likely pathogenic variants and variants of uncertain significance across 26 clinically actionable genes in 119 (35.52%) of 335 cases. The SAI HCM exhibited significantly fewer variants in the 12 definitive category genes compared with other global HCM cohorts (15.77% versus 43.23%; P <0.0001). For the 5 strong/moderate genes, no significant difference was observed between the SAI HCM and other global HCM cohorts (3.28% versus 2.73%; P =0.3499). Among the 21 limited and disputed genes, MYH6 showed a significantly higher prevalence of pathogenic/likely pathogenic variants in the SAI HCM than in the other global HCM cohorts (0.897% versus 0%; P =0.0287). Conclusions: The clinically actionable gene variants in SAI HCM differed significantly from other global HCM cohorts, specifically MYBPC3 , MYH7 , and MYH6 .

17 June 2026 in JACC: Advances
Verified
Journal Article
Open access
EREthan Rowin
Ethan Rowin
DLDeacon Z.J. Lee
Deacon Z.J. Lee
MSMark V. Sherrid
Mark V. Sherrid
BMBarry J. Maron
Barry J. Maron
ATAlbree F. Tower-Rader
Albree F. Tower-Rader
RCRaymond H. Chan
Raymond H. Chan
Apical aneurysms in hypertrophic cardiomyopathy (HCM) have been linked to sudden cardiac death (SCD) and a nidus for thromboembolism. Uncertainty remains regarding the level of risk and significance of aneurysm size. The objective of the study was to determine the rate of SCD events and prevalence of apical thrombus or embolic events by size (maximum transverse dimension). Apical aneurysms were identified in 510 patients from 10 centers, followed a median of 4.1 years for SCD events (SCD, appropriate implantable cardioverter defibrillator therapy, and resuscitated SCD) or development of apical thrombus/thromboembolism. Relationship between size and SCD events was analyzed using multivariable Cox proportional hazard models. In 510 HCM patients: 19% had small aneurysms (<10 mm), 39% medium (10-19 mm), 39% large (20-39 mm), and 3% very large (≥40 mm). SCD event rate was 2.1%/year, with risk increasing with increasing aneurysm size: 0.2%/year in small, 2.3%/year in medium, 3.0%/year in large and 8.2%/year in very large (P < 0.001). On multivariable analysis, greater size was associated with SCD events, independent of other risk markers or European Society of Cardiology-SCD score. Either an embolic event (3.6% of patients) or apical thrombus (10% of patients) occurred in 13% of patients and was independently associated with greater aneurysm size, 3% in small to 25% in very large aneurysms (P < 0.001). In a large cohort of HCM patients with apical aneurysms, rates of SCD events were high, with continuous relationship between size and risk. Small aneurysms (2%/year). Although embolic events were uncommon, increasing aneurysm size was associated with the prevalence of apical thrombi.